Topline Data from Phase 3 Trial shows beneficial effect of Givinostat 22nd June, 2022: Italfarmaco Group announced positive topline data from its completed Phase 3 EPIDYS trial with Givinostat, the company’s proprietary histone deacetylase (HDAC) inhibitor, in boys with Duchenne Muscular Dystrophy (DMD). The primary objective of the study was to evaluate the effects of Givinostat…
Prolonged release capsules for pain
Neuraxpharm launches Tapimio® (tapentadol) prolonged release capsules in the UK Neuraxpharm announced on June 30th 2022 the launch of Tapimio® (tapentadol) for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics. Tapimio® is the first and only prolonged release capsule formulation of tapentadol to be made available…
Preserving cognitive function in RRMS
Bristol Myers Squibb presents new data showing effect of early Zeposia (ozanimod) treatment in improving and preserving cognitive function in people with Relapsing Multiple Sclerosis. On June 24th, Bristol Myers Squibb presented results of the DAYBREAK open-label extension trial at the 8th European Academy of Neurology Congress in Vienna, Austria. New post-hoc analyses from the Zeposia (ozanimod) Phase 3…
Aubagio study: no disease activity after 2 years
More than half (58% )of the people with multiple sclerosis (MS) treated with Aubagio (teriflunomide) showed no evidence of disease activity after two years on treatment, according to an Italian study. The study, “Evolution of teriflunomide use in multiple sclerosis: A real-world experience,” was published in the Journal of the Neurological Sciences. Aubagio is an oral disease-modifying therapy that has been…
Novel Early Intervention Study for Stroke Patients
MindMaze and The University of Auckland partner on novel early intervention study for stroke patients, expanding global breadth of research supporting the company’s brain tech solutions MindMaze, (digital therapeutics (DTx) for neurological recovery and care), in partnership with The University of Auckland, has announced a new interventional study that will aim to show the merits…
Trial failure for Jazz Pharmaceuticals’ cannabis-derived drug in MS
Jazz Pharmaceuticals nabiximols oromucosal spray did not meet the primary endpoint in a phase 3 trial, failing in its aim of improving Lower Limb Muscle Tone-6 (LLMT-6) between baseline and Day 21, as measured by the Modified Ashworth Scale (MAS). The spray is formulated from extracts of the cannabis sativa plant and contains tetrahydrocannabinol (THC) and…
Promising interim results for Ajovy
PEARL STUDY Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment. 25th June 2022: Teva Pharmaceuticals Europe B.V. announced promising interim results from its Pan-European Real World study (PEARL),…
Breakthrough device for glioblastoma
Carthera receives FDA breakthrough device designation for SonoCloud-9 system, allowing for enhanced interaction with FDA and recognising SonoCloud system as innovative and promising approach for treatment of recurrent glioblastoma Carthera, a French company that designs and develops SonoCloud, an ultrasound-based medical device to treat a wide range of brain diseases, announced on June 22 2022 that…
Study: Improvements in TBI Patients with Persistent Brain Fog
A new study has shown that plasticity-based brain training can drive improvements in patients with persistent symptoms of Traumatic Brain Injury (TBI). Gains were observed in standard measures of cognition, standard measures of self-reported symptoms, and the connectivity between brain regions. The intervention used in the study was brain exercises from BrainHQ, made by Posit…
